Hansa Biopharma AB (publ) (0RC7)

Overview

Hansa Biopharma AB (publ), founded in 2007 and headquartered in Lund, Sweden, is a pioneering biopharmaceutical entity dedicated to the discovery, development, and commercialization of novel treatments for patients undergoing rare immunological conditions across Europe and the United States. The company leverages its expertise in immunology to address the unmet medical needs of patients suffering from conditions that are often overlooked, providing them with hope and potentially life-changing therapies. Their approach combines advanced research in immunoglobulin G (IgG) antibodies with innovative biotechnological methods, aiming to pave new pathways in the treatment of sensitized transplant patients, autoimmune diseases, and cancer.

Products and Services

Idefirix (imlifidase)

Idefirix is a groundbreaking product developed by Hansa Biopharma for the desensitization treatment of sensitized adult kidney transplant patients who exhibit a positive crossmatch test. This revolutionary therapy works by targeting and cleaving all classes of IgG antibodies, a necessary step for patients with high immunological risks to successfully receive kidney transplants. Idefirix has emerged as a vital pre-transplantation treatment, enhancing the possibility of successful organ transplantation for those previously deemed untreatable due to their sensitization status.

Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR)

NiceR represents an innovative advancement in the treatment of autoimmune diseases, transplantation, and oncology. By specifically focusing on creating novel immunoglobulin cleaving enzymes that can be administered in multiple doses, NiceR aims to offer long-term management options for these conditions. This initiative reflects Hansa Biopharma's commitment to extending their enzyme technology beyond acute treatments, paving the way for therapies that can potentially alter the course of autoimmune diseases and provide sustainable solutions in transplantation and cancer treatment.

Enzyme based antibody Enhancement (EnzE)

EnzE is an enzyme-based approach to cancer immunotherapy developed by Hansa Biopharma. By leveraging enzymes that can modify or enhance the body's antibody responses, EnzE aims to boost the immune system's ability to fight cancer more effectively. This innovative approach to cancer treatment exemplifies Hansa Biopharma's dedication to exploring new frontiers in immunology, providing hope for oncology patients through groundbreaking immunotherapeutic strategies.

Collaborations for Broader Impacts

Hansa Biopharma extends its research and development efforts through strategic collaborations with industry leaders.​ These partnerships, including agreements with Sarepta Therapeutics, AskBio, and Genethon, focus on assessing imlifidase's potential as a pre-treatment in various genetic disorders such as limb-girdle muscular dystrophy (LGMD), duchenne muscular dystrophy (DMD), pompe disease, and Crigler-Najjar syndrome in patients with anti-AAV antibodies. These collaborations highlight Hansa Biopharma's commitment to leveraging its enzyme technology platform, not only for transplant and autoimmune patients but also for gene therapy, expanding its impact on rare diseases and conditions beyond its core focus areas.